SpringWorks Therapeutics Newsroom

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus estimated revenue n

Simply Wall StMay 11 08:57 ET

SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference

STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announ

GlobeNewswireMay 8 07:00 ET

Express News | HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target

BenzingaMay 6 06:35 ET

SpringWorks Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 64.04% HC Wainwright & Co. → $74 Reiterates Buy → Buy 03/06/2024 66.26% JP Morgan $74 → $75 Mai

BenzingaMay 6 06:34 ET

Analysts Conflicted on These Healthcare Names: Springworks Therapeutics (SWTX) and Becton Dickinson (BDX)

TipRanksMay 6 03:01 ET

Earnings Call Summary | SpringWorks Therapeutics(SWTX.US) Q1 2024 Earnings Conference

The following is a summary of the SpringWorks Therapeutics, Inc. (SWTX) Q1 2024 Earnings Call Transcript:Financial Performance:SpringWorks Therapeutics reported revenue of $21 million after the succes

moomoo AIMay 5 02:40 ET · Conference Call

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Yahoo FinanceMay 3 08:41 ET

Express News | SpringWorks Therapeutics Inc : Wedbush Raises Target Price to $75 From $70

ReutersMay 3 02:18 ET

Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating

SpringWorks Therapeutics (SWTX) has an average rating of buy and price targets ranging from $58 to $80, according to analysts polled by Capital IQ. Price: 43.54, Change: -3.30, Percent Change: -7.05

MT NewswiresMay 2 12:25 ET

Express News | SpringWorks Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 EPS Results

BenzingaMay 2 10:52 ET

Express News | SpringWorks Therapeutics Shares Reverse Premarket Gains, Last Down 6.7%

ReutersMay 2 09:40 ET

Buy Rating for Springworks Therapeutics Amid Strong Market Performance and Promising Pipeline

TipRanksMay 2 09:37 ET

Express News | SpringWorks Therapeutics Shares up 6.7% Premarket After Q1 Results

ReutersMay 2 09:00 ET

Express News | Springworks' Cash, Cash Equivalents And Marketable Securities Were $573M As Of March 31, 2024

BenzingaMay 2 06:35 ET

Express News | SpringWorks Therapeutics : Cash, Cash Equivalents, & Marketable Securities: Cash, Cash Equivalents &Marketable Securities Were $573.0 Mln as of Mar 31

ReutersMay 2 06:31 ET

Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, Vs. Street Est of $13.1M

06:31 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, vs. Street Est of $13.1M

MT NewswiresMay 2 06:31 ET

Express News | SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

ReutersMay 2 06:30 ET

Express News | SpringWorks Therapeutics Q1 Basic EPS USD -1.18

ReutersMay 2 06:30 ET

Springworks Therapeutics (SWTX) Receives a Buy From Barclays

TipRanksMay 2 03:50 ET

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024

STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will

GlobeNewswireApr 18 07:00 ET